SBK Pharma

Active Risk: not assessed

Private limited companyfounded 2022active for 4 yearsRoute de Ster 3, 4970 Stavelot, BelgiumKBO/BCE: BE 0782.437.533

Summary

SBK Pharma is a financial institution. The bankruptcy model is trained on trading and manufacturing companies and does not apply here. The 2025 annual accounts show equity of €43,628 and a net result of €8,967. Equity has been growing by about 33% per year since 2023. Its solvency ranks better than 19% of 6,694 sector peers (NACE 64, financial year 2025). The company has been active since 2022 and the Belgian Official Gazette contains no insolvency or warning signals.

Risk analysisFollow Report Compare

SBK PharmaActive

Risk analysis Report Compare

Official details

Source: KBO

Status: Active since 21-02-2022 Normal situation
Activity: Activities of holding companies NACE 64210
Establishment unit: 2.328.617.533 4970 Stavelot, since 15-03-2022
Financial year end: 31 December
Peppol: Reachable since 01-10-2025

Company details

Board and ownership

Board

BECHET Monique Rose Renée DeniseDirector · since 21-02-2022

Shareholders

BECHET Monique Rose Renée Denise100 sharesact of 23-02-2022

Holdings: Shares in 1 company PharmaConseil

Board & ownership

Financial position

Financial institution: outside the modelBankruptcy probability: sector outside the model

Annual accounts 2025

Profit: €8,967; ▼ 35.7%
Equity: €43,628; ▲ 25.9%
Total assets: €256,504; ▲ 0.8%

Financials

SignalsneutralLatest accounts filed on timeShow the evidence

Checked score

Outside the general model

Model not applicable to financial institutions

The Checked score measures liquidity, leverage and margins against the norms for trading and manufacturing companies. A bank, insurer or financial holding has a very different balance sheet. Those ratios and the score mean nothing here. So there is no financial strength either.

Bankruptcy probability within 12 months

The company is a financial institution: a bank, insurer or financial holding. Its balance sheet works differently from that of a trading or manufacturing company. A bankruptcy probability from the general model would mislead here.

Credit check for an amount and term of your choice

Show the recommended maximum and see how the verdict changes with amount, term and advance.

The scores and ratios are Checked's own calculations, not a credit decision.

Signals

1 signal.

neutral

Latest accounts filed on time

The financial year that closed on 31-12-2025 was due by 31-07-2026 and was filed on 16-07-2026, 15 days ahead of the deadline.

NBB · 3 filings

Deviation from the deadline

2025

15 days early

2024

10 days early

2023

8 days early

← before the deadline after the deadline →

tick = median of all Belgian filingsring = median in the sector

The company filed its last 3 accounts on average 11 days before the deadline. In the sector (NACE 64), the median for financial year 2024 was 14 days before the deadline, and 28% of those companies filed late.

Searched, nothing found (2)

Next filing not due yet

The next financial year closes on 31-12-2026 and is due by 31-07-2027. Nothing is late today. The company usually files around 21 July (3 of the last 3 accounts filed within 30 days either side of that date).

Companies Code · seven months

Where today falls in the filing period

04-11-2026 today31-12-2026 year end31-07-2027 deadline

No strike-offs in the KBO publications

That holds for every publication since incorporation in 2022.

KBO publications

Key points

Caution: Less equity than 87% of companies in financial servicessector median €581,036 · 6,695 companies €43,628 View

Recent changes

23-02-2022 · Gazette deed IncorporationStarting capital €6,000 · Appointment: BECHET Monique Rose Renée Denise (director) · Founder: BECHET Monique Rose Renée Denise · Founding capital €6,000, 100 shares

All 5 events

Comparable companies

These companies have the same main activity as SBK Pharma: activities of holding companies (NACE 64210). They are comparable in size and age: total assets between €238,000 and €344,000, founded between 2021 and 2022.

Company	Total assets	Gross margin
SBK Pharma Stavelot	€256,504	€14,431
MAJAJUDA Gouvy	€264,729	€15,222
CBplus Zulte	€280,190	€15,823
PC MGT Tienen	€291,633	€13,052
OffshoreWind.io Tervuren	€237,718	€18,348
ACT Projects Kelmis	€263,977	€11,977
L E M FORWARD Aywaille	€344,056	€15,912

Full comparison

Key facts about SBK Pharma

What is the company number of SBK Pharma?: The company number of SBK Pharma is 0782.437.533. The VAT number is the same number with BE in front: BE 0782.437.533.
Where is SBK Pharma based?: The registered office is at Route de Ster 3, 4970 Stavelot.Company details
What does SBK Pharma do?: According to the KBO register, the main activity is activities of holding companies (NACE 64210).
What is the legal form of SBK Pharma?: The legal form of SBK Pharma is Private limited company (BV).
When was SBK Pharma founded?: SBK Pharma was founded on 21-02-2022.
Is SBK Pharma still active?: Yes, SBK Pharma is an active enterprise in the KBO register.
What is the turnover of SBK Pharma?: The turnover in financial year 2025 is ≈ €70,000. This figure is estimated from the gross margin of €14,431 and 54 comparable companies (NACE 64210). It probably lies between €36,000 and €120,000. It is a rough estimate.Financials
Is SBK Pharma profitable?: In financial year 2025, SBK Pharma made a profit of €8,967.
Where can I find the annual accounts of SBK Pharma?: SBK Pharma filed 3 annual accounts with the National Bank of Belgium, the latest for financial year 2025.
When are the next annual accounts of SBK Pharma due?: SBK Pharma must file the annual accounts for financial year 2026 by 31-07-2027.Timeline